Novartis has filed the PD-1 inhibitor tislelizumab, licensed from BeiGene, for second-line esophageal cancer with the FDA, the first submission outside China for the closely-watched therapy.
Novartis AG's plans to get a slice of the global anti-PD-1/L1 market have advanced with the news that the US Food and Drug Administration has accepted a submission for tislelizumab, licensed from China's BeiGene, Ltd., as a treatment for esophageal cancer.
The agency has set a Prescription Drug User Fee Act target action date of July 12 next year for its...
The drugmaker presented data at a lymphoma meeting showing strong efficacy for the CAR-T in marginal zone lymphoma, the second most common indolent lymphoma.
First results for a first-in-class mutCALR-targeted therapy in essential thrombocythemia presented at EHA point to a lucrative future for the early-stage product.
In this week's episode: breaking down big pharma’s executive pay; US vaccine panel upheaval; Merck’s RSV approval; MFN and Japan; and the future of Pfizer and Arvinas’s partnership.
